WO1997015668A3 - Methods and compositions comprising glut-2 and glut-2 chimeras - Google Patents

Methods and compositions comprising glut-2 and glut-2 chimeras Download PDF

Info

Publication number
WO1997015668A3
WO1997015668A3 PCT/US1996/017327 US9617327W WO9715668A3 WO 1997015668 A3 WO1997015668 A3 WO 1997015668A3 US 9617327 W US9617327 W US 9617327W WO 9715668 A3 WO9715668 A3 WO 9715668A3
Authority
WO
WIPO (PCT)
Prior art keywords
glut
methods
compositions
cell killing
transporters
Prior art date
Application number
PCT/US1996/017327
Other languages
French (fr)
Other versions
WO1997015668A2 (en
Inventor
Christopher B Newgard
Samuel A Clark
Anice E Thigpen
Karl D Normington
Original Assignee
Univ Texas
Betagene Inc
Christopher B Newgard
Samuel A Clark
Anice E Thigpen
Karl D Normington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Betagene Inc, Christopher B Newgard, Samuel A Clark, Anice E Thigpen, Karl D Normington filed Critical Univ Texas
Priority to EP96937792A priority Critical patent/EP0857212A2/en
Priority to AU75254/96A priority patent/AU7525496A/en
Publication of WO1997015668A2 publication Critical patent/WO1997015668A2/en
Publication of WO1997015668A3 publication Critical patent/WO1997015668A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

The present invention provides compositions and various novel uses of the glucose transporter, GLUT-2. Included are methods of using GLUT-2 in cell killing, such as in negative selection and double selection protocols in vitro, in screening methods for identifying genes, promoters and substrates, and in cell killing in vivo, such as may be used in cancer treatment. Also provided are modified functional glucose transporters resistant to diabetic immune attack and methods of making and using such transporters.
PCT/US1996/017327 1995-10-23 1996-10-23 Methods and compositions comprising glut-2 and glut-2 chimeras WO1997015668A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96937792A EP0857212A2 (en) 1995-10-23 1996-10-23 Methods and compositions comprising glut-2 and glut-2 chimeras
AU75254/96A AU7525496A (en) 1995-10-23 1996-10-23 Methods and compositions comprising glut-2 and glut-2 chimeras

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54693495A 1995-10-23 1995-10-23
US08/546,934 1995-10-23

Publications (2)

Publication Number Publication Date
WO1997015668A2 WO1997015668A2 (en) 1997-05-01
WO1997015668A3 true WO1997015668A3 (en) 1997-07-24

Family

ID=24182621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/017327 WO1997015668A2 (en) 1995-10-23 1996-10-23 Methods and compositions comprising glut-2 and glut-2 chimeras

Country Status (3)

Country Link
EP (1) EP0857212A2 (en)
AU (1) AU7525496A (en)
WO (1) WO1997015668A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2002043770A2 (en) * 2000-12-01 2002-06-06 Conforma Therapeutic Corporation Homing peptide multimers, their preparation and uses
EP2610265B1 (en) 2003-05-02 2016-11-16 Centre National de la Recherche Scientifique (C.N.R.S.) Glut-1 as a receptor for HTLV envelopes and its uses
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
EP1586650A1 (en) * 2004-04-16 2005-10-19 ProBioGen AG Intervention in the energy metabolism of eukaryotic cells for selection and increase of expression
WO2007021423A2 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5624994B2 (en) 2009-01-09 2014-11-12 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク New receptor binding ligands, their use in the detection of cells of biological interest
WO2023064871A1 (en) 2021-10-14 2023-04-20 Asimov Inc. Integrases, landing pad architectures, and engineered cells comprising the same
WO2023086822A2 (en) 2021-11-09 2023-05-19 Asimov Inc. Stable production systems for aav vector production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001281A1 (en) * 1991-07-03 1993-01-21 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5366874A (en) * 1992-01-02 1994-11-22 Board Of Regents, The University Of Texas System Molecular cloning and expression of biologically-active diphtheria toxin receptor
WO1994028143A1 (en) * 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
WO1995000644A1 (en) * 1993-06-28 1995-01-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001281A1 (en) * 1991-07-03 1993-01-21 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5366874A (en) * 1992-01-02 1994-11-22 Board Of Regents, The University Of Texas System Molecular cloning and expression of biologically-active diphtheria toxin receptor
WO1994028143A1 (en) * 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
WO1995000644A1 (en) * 1993-06-28 1995-01-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1993, WILEY & SONS, NEW YORK, US, XP002032038 *
BELL ET AL.: "Molecular biology of mammalian glucose transporters", DIABETES CARE, vol. 13, no. 3, March 1990 (1990-03-01), pages 198 - 208, XP000674437 *
FRAM AND ROBICHAUD: "Mechanisms underlying resistance to Streptozotocin in Mer+ and Mer- human tumor lines", BIOCHEMICAL PHARMACOLOGY, vol. 39, no. 5, 1 March 1990 (1990-03-01), pages 959 - 964, XP000674232 *
HANAHAN D: "HERITABLE FORMATION OF PANCREATIC BETA-CELL TUMOURS IN TRANSGENIC/ MICE EXPRESSING RECOMBINANT INSULIN/SIMIAN VIRUS 40 ONCOGENES", NATURE, vol. 315, 9 May 1985 (1985-05-09), pages 115 - 122, XP002024933 *
HUGHES ET AL.: "Transfection of AtT-20ins cells with Glut-2 but not Glut-1 confers glucose-stimulated insulin secretion", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 20, 15 July 1993 (1993-07-15), pages 15205 - 15212, XP002032034 *
KATAGIRI ET AL.: "Replacement of intracellular C-terminal domain of Glut-1 glucose transporter with that of Glut-2 increases Vmax and Km of transport activity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 31, 5 November 1992 (1992-11-05), pages 22550 - 22555, XP002032035 *
MUECKLER ET AL.: "A mutation in the Glut-2 glucose transporter gene of a diabetic patient abolishes transport activity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 27, 8 July 1994 (1994-07-08), pages 17765 - 17767, XP002032036 *
NEWGARD C.B.: "Cellular engineering for the treatment of metabolic disorders: prospects for therapy in diabetes", BIO/TECHNOLOGY, vol. 10, October 1992 (1992-10-01), pages 1112 - 1120, XP002032062 *
PATER AND PATER: "Thymidine kinase of Herpes Virus as a vehicle for the isolation and characterization of unknown mammalian promoters and enhancers", JOURNAL OF MOLECULAR AND APPLIED GENETICS, vol. 2, no. 4, 1984, pages 363 - 371, XP000674297 *
PIEPER ET AL.: "Effects of Streptozotocin/Bis-chloroethylnitrosourea combination therapy on O6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro", CANCER RESEARCH, vol. 51, 15 March 1991 (1991-03-15), pages 1581 - 1585, XP000674346 *
RAUCHMAN ET AL.: "Expression of Glut-2 cDNA in human B lymphocytes: analysis of glucose transport using flow cytometry", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1111, 1992, pages 231 - 238, XP000674407 *
SCHNEDL W J ET AL: "STZ TRANSPORT AND CYTOTOXICITY SPECIFIC ENHANCEMENT IN GLUT2-EXPRESSING CELLS", DIABETES, vol. 43, no. 11, November 1994 (1994-11-01), pages 1326 - 1333, XP000616508 *
YOUNG-PING HWUNG ET AL: "COOPERATIVITY OF SEQUENCE ELEMENTS MEDIATES TISSUE SPECIFICITY OF THE RAT INSULIN II GENE", MOLECULAR AND CELLULAR BIOLOGY, vol. 10, no. 4, April 1990 (1990-04-01), pages 1784 - 1788, XP002024994 *

Also Published As

Publication number Publication date
WO1997015668A2 (en) 1997-05-01
AU7525496A (en) 1997-05-15
EP0857212A2 (en) 1998-08-12

Similar Documents

Publication Publication Date Title
AU2369595A (en) In vitro growth of functional islets of langerhans and in vivo uses thereof
TW428026B (en) Bifunctional protein, preparation and use
AU2836995A (en) Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
EP1923467A3 (en) Adenovirus vectors for gene therapy
CA2277896A1 (en) Preparation of collagen
HK1042496B (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
IL117425A0 (en) Receptor activation by gas6
EP2172476A3 (en) Compositions and methods for WT1 specific immunotherapy
CA2347979A1 (en) Treatment of skin with adenosine or adenosine analog
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
AU6589094A (en) 7-deazapurine modified oligonucleotides
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
WO1995024497A3 (en) Enzymatic preparation of polysaccharides
WO1996021468A3 (en) Chemically modified interferon
WO1997015668A3 (en) Methods and compositions comprising glut-2 and glut-2 chimeras
WO2000015665A3 (en) A method of producing a functional immunoglobulin superfamily protein
WO1998039034A3 (en) Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
WO2002078526A3 (en) Cancer-testis antigens
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
AU6921300A (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
WO2001032927A3 (en) Tissue specific genes of diagnostic import
AU5318496A (en) Adenovirus vectors for gene therapy
ATE546457T1 (en) METHOD AND COMPOSITIONS FOR PRODUCING C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU3189199A (en) Antisense modulation of lfa-3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BA BB BG CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BA BB BG CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW KE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996937792

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996937792

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97516861

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996937792

Country of ref document: EP